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Choosing Wisely (CW) is a medical stewardship initiative led by the American Board of Internal Medicine
Foundation in collaboration with professional medical societies in the United States. In an effort to learn
from and leverage the work of others, the American Society of Hematology CW Task Force developed a
method to identify and prioritize CW recommendations from other medical societies of high relevance and
importance to patients with blood disorders and their physicians. All 380 CW recommendations were
reviewed and assessed for relevance and importance. Relevance was assessed using the MORETM relevance
scale. Importance was assessed with regard to six guiding principles: harm avoidance, evidence, aggregate
cost, relevance, frequency and impact. Harm avoidance was considered the most important principle. Ten
highly relevant and important recommendations were identified from a variety of professional societies.
Recommendations focused on decreasing unnecessary imaging, blood work, treatments and transfusions, as
well as on increasing collaboration across disciplines and considering value when recommending
treatments. Many CW recommendations have relevance beyond the society of origin. The methods
developed by the ASH CW Task Force could be easily adapted by other Societies to identify additional CW
recommendations of relevance and importance to their fields.
Am. J. Hematol. 91:787–792, 2016. VC 2016 Wiley Periodicals, Inc.
 Introduction
Choosing Wisely (CW) is a medical stewardship campaign initiated by the American Board of Internal Medicine (ABIM) Foundation. To date
more than 60 different medical professional societies have participated in the campaign by creating and promoting lists of tests and treatments
that physicians and patients should question. The campaign has had a broad impact in healthcare, both by increasing awareness of overutilization
[1], and in some instances by triggering changes in practice [2].
Since the CW campaign began in 2012 the number of participating societies and subsequent recommendations have grown dramatically. There
are more than 380 CW recommendations listed on the ABIM website [3]. Many of the recommendations have relevance beyond the field from
which they originated. Yet strategies to raise awareness of CW recommendations have tended to direct clinicians to recommendations made by
their parent societies [4]. Increasing awareness of a wider breadth of recommendations may ultimately help clinicians curb overutilization in
medicine.
The American Society of Hematology (ASH) has previously released two lists of Choosing Wisely recommendations [5,6]. In 2015, the ASH
CW Task Force developed a methodology to systematically identify and prioritize CW recommendations from other professional societies of rele-
vance and importance to the practice of hematology. A top ten list of non-ASH CW recommendations relevant and important to the care of
patients with blood conditions was developed and is presented below.
 Methods
A two phase process was developed to identify and rank non-ASH CW recommendations. First, the ASH CW Task Force independently scored all ABIM CW recommenda-
tions on the McMaster On-line Rating of Evidence (MORETM) relevance scale, a previously described seven-point Likert scale used to assess medical relevance (see Table I)
[7]. Scores were summarized and modified group technique was used to identify the top 50 unique non-ASH CW recommendations with regard to relevance [8]. Overlapping
recommendations from different societies were grouped together as one recommendation. The kappa statistic for multiple raters [9] was calculated using Stata 13 (StataCorp.
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). For the purpose of estimating inter-rater agreement the MORE score was collapsed into a binary
outcome where scores of one to three indicated lack of relevance and scores of four to seven indicated possible relevance.
1St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2University of Florida, Gainesville, Florida; 3Harvard Vanguard Medical Associates, Beverly,
Massachusetts; 4Washington University, St. Louis, Missouri; 5Medical Specialists of Taunton, Taunton, Massachusetts; 6University of Toronto, University Health Net-
work, Toronto, Ontario; 7University of North Carolina, Chapel Hill, North Carolina; 8All Children’s Hospital Johns Hopkins Medicine, St. Petersburg, Florida; 9Nation-
wide Children’s Hospital, Columbus, Ohio; 10Medical College of Wisconsin/Children’s Hospital of Wisconsin, Milwaukee, Wisconsin; 11Medical College of Wisconsin,
Milwaukee, Wisconsin; 12UT Southwestern Medical Center, Dallas, Texas
†Listed in alphabetical order due to equal contributions.
Disclosure: The authors declare no competing financial interests.
*Correspondence to: Lisa K. Hicks; 30 Bond St. Rm 2-084 Donnelly Wing, Toronto, ON M5B 1W8, Canada. E-mail: hicksl@smh.ca
Received for publication: 26 January 2016; Revised: 26 April 2016; Accepted: 3 May 2016
Am. J. Hematol. 91:787–792, 2016.
Published online: 6 May 2016 in Wiley Online Library (wileyonlinelibrary.com).
DOI: 10.1002/ajh.24412
VC 2016 Wiley Periodicals, Inc.
doi:10.1002/ajh.24412 American Journal of Hematology, Vol. 91, No. 8, August 2016 787
RESEARCH ARTICLE AJH
In the second phase of the project, the ASH CW Task Force was asked to score
each of the remaining 50 CW recommendations between one and ten for prioritiza-
tion for inclusion on a top ten list of non-ASH CW recommendations. Task force
members were asked to consider the six guiding principles outlined in Table II
(listed in order of importance). Avoiding harm to patients was considered the pre-
eminent guiding principle. Modified group technique [8] was used to select the top
ten CW recommendations from other specialty societies of relevance and impor-
tance to the care of patients with hematologic disease.
The ASH CW Task Force was comprised of 13 members: five men and eight
women. All 13 members participated in both phases of item selection. Malignant,
nonmalignant, lab-based, adult and pediatric hematologists were all represented on
the Task Force.
 Results
All ABIM CW recommendations posted on the ABIM CW web-
site [5] were compiled at the end of April, 2015. At that time, there
were 65 participating professional societies (excluding ASH) con-
tributing 5–15 recommendations each, for a total of 380 individual
recommendations. 261 (69%) of the CW recommendations received
an average relevance score of less than four suggesting limited rele-
vance to the practice of hematology. The kappa statistic for inter-
rater agreement was 0.43, suggesting moderate inter-rater agree-
ment on relevance [10]. The top ten CW recommendations from
other professional societies relevant and important to the care of
patients with blood diseases are outlined in Table III. The high-
lighted CW recommendations come for 13 different societies. Two
of the recommendations were made by three or more different spe-
cialty societies.
 Discussion
The first CW recommendation on our top ten list is an item that
recommends against imaging for pulmonary embolism (PE) in the
absence of moderate or high pretest probability. Slightly different ver-
sions of this recommendation were made by the American College of
Radiology, the American College of Physicians, the American College
of Chest Physicians and American Thoracic Society, and the Ameri-
can College of Emergency Physicians. The number of societies mak-
ing this recommendation likely reflects both its importance and the
large number of medical specialties involved in the diagnosis and
management of PEs.
Recent data suggests that computed tomography scans with pul-
monary angiography (CT-PA’s) are being overemployed in all clinical
settings to investigate for the possibility of a PE [11]. Poor patient
selection, ready access to CT-PAs, patient expectations, and concern
for malpractice litigation all likely contribute to overutilization of this
imaging modality. Importantly however, despite a dramatic increase
in the use of CT-PA’s over the recent years, there is no evidence that
clinically important patient outcomes have improved. Therefore, the
risks and benefits of CT-PA’s should be carefully considered and our
current practice patterns for the evaluation of PE should be re-
examined to align with evidence-based guidelines.
CT-PA’s deliver between 2.2 and 7 mSv of radiation depending on
body habitus and protocol [12]. This dose of radiation has been asso-
ciated with a small, but significant increased life-time risk of cancer,
particularly in young women where radiation-induced breast cancer
is a concern [13–15]. Contrast-induced nephropathy is also a concern
especially in patients who may subsequently be started on anticoagu-
lation. Scans also frequently detect incidental findings triggering fur-
ther testing with incumbent risks. The improved resolution of CT-
PA’s has led to increased detection of small subsegmental PE’s.
Whether these PE’s truly warrant aggressive anticoagulation to
improve patient outcomes is debated [16].
Importantly, in the setting of low pretest probability imaging for
PE is likely unnecessary. Diagnostic algorithms utilizing clinical fea-
tures such as the Wells criteria, PERC tool and sensitive D-dimer test-
ing can be used to safely rule out PE in many low risk patients
without the need for imaging [17]. A large meta-analysis of 12 studies
showed that the overall proportion of missed PE’s using the PERC
tool was only 0.3% [18]. More recently, a randomized controlled trial
also suggested that utilizing pretest probability to avoid imaging in
low risk patients is both safe and cost-saving [19]. Taken together,
there is an urgent need for institutions to develop protocols incorpo-
rating clinical decision rules and laboratory data to optimally rule out
PE while minimizing the number of patients exposed to CT-PA’s.
The second CW item of high relevance and importance to hema-
tology is a recommendation against routine inherited thrombophilia
testing in patients undergoing an infertility evaluation. This recom-
mendation comes from the American Society for Reproductive Medi-
cine and is a commonly faced reason for hematology referral by both
patients and their providers. Infertility is an extremely common dis-
order affecting 5–15% of women [20,21]. Given the potential fre-
quency of infertility evaluation and the broad differential diagnosis of
infertility, investigations should be judicious, evidence-based, and
should minimize harm to the patient. Conflicting reports exist regard-
ing a possible association between inherited thrombophilia and infer-
tility [22,23]. On balance, the evidence does not support a strong
association. More importantly, studies demonstrating that thrombo-
philia test results can be successfully used to guide management of
infertility are lacking. Thrombophilia testing in any setting is fraught
with false interpretation of tests leading to perpetuation of a throm-
bophilia diagnosis in the patient’s medical records, high costs and
minimal potential benefit. Further, inappropriate thrombophilia test-
ing could potentially also lead to inappropriate use of anticoagulants,
increased patient anxiety and difficulties obtaining insurance in these
young and typically healthy individuals. Low-molecular weight hepa-
rin, even in prophylactic doses during pregnancy, can have several
drawbacks including the inconvenience of daily self-injections, cost,
bleeding, and decreased access to neuroaxial anesthesia if used in
TABLE I. The MORETM Scale for Relevance
Score Description
7 Directly and highly relevant
6 Definitely relevant
5 Probably relevant
4 Possibly relevant—Likely of indirect or peripheral
relevance at best
3 Possibly not relevant
2 Probably not relevant: content only remotely related
1 Definitely not relevant: completely unrelated content area
TABLE II. Guiding Principles for the ASH Choosing Wisely Campaign
1. Harm avoidance Recommendations should aim to reduce poten-
tial harm to patients
2. Evidence Recommendations should be evidence-based
3. Cost Recommendations should aim to decrease the
cost of health care
4. Frequency Recommendations should target tests, proce-
dures or treatments that are common
5. Purview of the
hematologist
Recommendations should target tests, proce-
dures or treatments within the purview of the
hematologist
6. Impact Recommendations that are likely to have greater
impact (lead to greater positive changes)
should be prioritized over those of lesser
impact
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proximity to delivery time. Therefore, widespread testing for congeni-
tal thrombophilia in the infertility setting could have substantial
resource implications with little anticipated benefit.
The third CW recommendation of high importance and relevance
to the care of patients with blood diseases is from the Society of Hos-
pital Medicine and recommends against repetitive complete blood cell
and chemistry testing in the face of clinical and lab stability. Similar
recommendations were made by the American Association of Blood
Banks (AABB) and the Critical Care Societies Collaborative—Critical
Care. Human blood is a scarce resource. It has been estimated that
every year four times as much blood is collected for testing, and ulti-
mately disposed of, than is transfused worldwide (24). Laboratory
testing is the single-highest practiced medical activity across all spe-
cialties and health care settings. Approximately 27% of all orders on
admission are avoidable and 63% of orders are avoidable for the
remainder of the hospitalization [25]. Only 1–5% of laboratory tests
result in some form of management action by the health care team
[26]. Routine laboratory tests not only increase direct costs but also
increase aggregate indirect expenses from subsequent downstream
activities, such as prescriptions, imaging, surgeries, lengthened hospi-
tal stays, all of which place patients at risk for preventable medical
errors. Furthermore, patients are subjected to these unnecessary labo-
ratory tests that yield no information or, worse, misinformation.
Interestingly, geographic differences in laboratory utilization exist
without any obvious disparity in quality of care or clinically relevant
outcomes [27]. In both the inpatient and outpatient setting a growing
body of literature documents a low diagnostic yield from routine
blood work [28,29]. Moreover, anemia caused by repeated blood
draws is a well-recognized complication of hospital care [30,31]. In
some patients without the bone marrow reserve or erythropoietin
drive to compensate for iatrogenic blood loss, repeated lab tests can
lead to otherwise preventable packed red cell transfusions which have
inherent risks. In critical care units, prospective data suggest that
strategies to reduce daily blood draws result in less anemia, substan-
tial cost-saving, and have no negative impact on other clinical out-
comes [29,31]. A simple and effective educational intervention of
informing physicians of the charges for laboratory tests and their per-
sonal utilization patterns has been shown to reduce the number of
laboratory tests ordered and laboratory expenditures [32]. It is recom-
mended that blood testing be part of a reasoned diagnostic and man-
agement plan as opposed to automatic. Thus in some settings daily
blood work may be appropriate for a short period of time; while in
others no blood tests may be required. Developing test-ordering con-
tainment strategies through multidimensional approaches aimed at
changing provider and system culture affords an opportunity to
improve quality and reduce costs. Given their understanding of iatro-
genic anemia, and their placement as leaders in the laboratory and
transfusion environments, many hematologists are well positioned to
develop initiatives addressing this type of overutilization.
The fourth CW recommendation selected by the ASH CW task
force is a recommendation from the AABB CW campaign. The
AABB advises against transfusing red blood cells for iron deficiency
in the absence of hemodynamic instability. This is a particularly rele-
vant recommendation for the hematologist as iron deficiency anemia
due to a variety of causes is an extremely common reason for consul-
tation with a hematologist. Iron deficiency is under-recognized,
under-treated, or not properly followed in transitions of health care
settings in 35–65% of cases [33–35]. In addition, patients at risk for
developing iron deficiency (e.g., bariatric surgery patients) are often
inadequately monitored or educated on the signs and symptoms of
iron deficiency leading to late stage presentations. Despite the avail-
ability of cheaper and safer therapies for iron deficiency anemia,
packed red blood cell transfusions have become a reflexive approach.
A proactive strategy of treating iron deficiency anemia before it
becomes severe is vital. Many patients with moderate to severe
chronic iron deficiency anemia have healthy hematopoietic systems
and will undergo brisk erythropoiesis when iron deficiency is cor-
rected. Furthermore, preoperative patients with iron deficiency should
TABLE III. The Top Ten Non-ASH Choosing Wisely Recommendations of Relevance and Importance to Hematology
Recommendation Professional society
1. Don’t image for suspected pulmonary embolism (PE) without moderate or high pretest
probability.a
American College of Radiology
American College of Physicians
American College of Chest Physicians
and American Thoracic Society
American College of Emergency Physicians
2. Don’t routinely order thrombophilia testing on patients undergoing a routine infertility
evaluation.
American Society for Reproductive Medicine
3. Don’t perform repetitive CBC and chemistry testing in the face of clinical and lab
stability.b
Society of Hospital Medicine -
Adult Hospital Medicine
American Association of Blood Banks
Critical Care Societies Collaborative—Critical Care
4. Don’t transfuse red blood cells for iron deficiency without hemodynamic instability. American Association of Blood Banks
5. Avoid using PET or PET-CT scanning as part of routine follow-up care to monitor for a
cancer recurrence in asymptomatic patients who have finished initial treatment to elimi-
nate the cancer unless there is high-level evidence that such imaging will change the
outcome
American Society of Clinical Oncology
6. Don’t delay palliative care for a patient with serious illness who has physical, psycholog-
ical, social or spiritual distress because they are pursuing disease-directed treatment
American Academy of Hospice a
nd Palliative Medicine
7. Don’t place, or leave in place, peripherally inserted central catheters for patient or pro-
vider convenience
Society of General Internal Medicine
8. Don’t use white cell stimulating factors for primary prevention of febrile neutropenia for
patients with less than 20 percent risk for this complication
American Society of Clinical Oncology
9. Don’t use expensive medications when an equally effective and lower-cost medication
is available
American College of Preventive Medicine
10. Don’t routinely transfuse fresh frozen plasma and platelets prior to abdominal para-
centesis or endoscopic variceal band ligation
American Association for the Study
of Liver Diseases
a Wording reflects that of the Radiology recommendation, other listed societies have similar recommendations, some explicitly recommended D-Dimer test-
ing prior to imaging.
b Wording reflects that of the Society of Hospital Medicine, other listed Societies made similar recommendations.
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be treated early with oral or intravenous iron, when appropriate, to
avoid preventable intraoperative transfusion.
Although generally low, the risk of adverse events from transfu-
sion, including alloimmunization, transfusion reactions, and infection
are higher than the risks of adverse events from oral or intravenous
iron replacement [36,37]. Transfusion is also more costly than iron
replacement, particularly oral iron replacement which can cost as lit-
tle as five cents a day [33,38]. Thus in most cases it is both safer and
more cost-effective to correct iron deficiency, rather than to transfuse
red blood cells. Despite this, observational data suggests that iron
replacement is under-utilized in adult and pediatric settings, and that
transfusion continues to be used unnecessarily as a first-line strategy
for severe, but stable iron deficiency anemia [39–41].
The fifth CW item highly relevant and important to the practice of
hematology is from ASCO. ASCO recommends that clinicians avoid
using positron emission tomography (PET) or PET-CT scanning to
routinely monitor for cancer recurrence in patients who have finished
cancer treatment and are asymptomatic. PET is an enormously
powerful diagnostic and staging tool in a wide variety of cancers.
However, there is little evidence that routine surveillance with PET
scans can improve clinical outcomes in malignant hematology. In fact
the limited observational data that is available suggests no survival
advantage with the use of routine surveillance PET scans in patients
with aggressive lymphoma [42,43]. Moreover, PET scanning is very
expensive and is associated with a significant dose of radiation which
is additive to radiation doses from CT. It has been estimated that
depending on the scanning protocol used, a single PET-CT scan in a
20-year old woman is associated with a 0.2–0.5% increased lifetime
attributable risk of cancer [44]. Lymphoma is the most common can-
cer among adolescents and young adults [45], thus it is important
that malignant hematologists are cognizant of the risks of surveillance
scans in young patients. In older patients, the attributable risk of can-
cer from scans is lower; however, there is also a risk of false positive
results, requiring additional tests with incumbent hazards and costs.
For all of these reasons, outside of a clinical trial, routine PET surveil-
lance is not recommended in the management of patients with blood
cancers.
The sixth item on ASH’s list of highly relevant and important CW
recommendations is an item from the American Academy of Hospice
and Palliative Medicine (AAHPM). The AAHPM recommends
against delaying palliative care for patients because they are pursuing
disease-directed treatment. Over the past decade palliative care has
transformed from a discipline concerned principally with alleviating
suffering in the final months of life, to a branch of medicine offering
guidance on improving quality of life for patients with serious ill-
nesses and expertise in end of life care [46]. This transformation is
extremely relevant to the care of patients with blood cancers.
A large body of literature suggests that patients with hematologic
malignancy are less likely to be referred to palliative care services
than patients with other cancers [47]. Patients with blood cancers are
also more likely to experience intensive end of life care [48]. These
findings are complex and likely in part reflect unique features of
hematologic cancers and historical barriers to accessing palliative
services for patients desiring transfusion or other forms of active
treatment [49,50]. Nonetheless, there is compelling evidence that early
involvement of palliative care services improves quality of life, patient
satisfaction, care giver satisfaction and in some settings can improve
overall survival [51–53]. Incorporating palliative care into cancer care,
particularly early in the patient journey may also offer the possibility
of substantial cost-savings [51,54]. Thus, increasing access to palliative
care for patients with blood cancers, including those pursuing
disease-directed treatment, may offer huge opportunities to improve
care while also reducing health care costs.
The seventh item highlighted by the ASH CW Task Force is a rec-
ommendation from the Society of General Internal Medicine that
advises clinicians not to place, or leave in place, peripherally inserted
central catheters for patient or provider convenience. Central lines
are frequently indicated in patients with blood diseases to facilitate
the administration of chemotherapy, other infusions, and/or blood
products in patients who have difficult intravenous access, require
vesicants, and/or need very frequent infusions. However, one-third of
central venous catheters are placed for “weaker” indications such as
facilitating blood draws or in case of clinical deterioration [55]. Fur-
ther, more than 15% of these patients will have a catheter related
complication [56]. Unfortunately, many patients for whom central
lines are helpful such as patients with cancer or sickle cell disease, are
also patients at especially high risk of line-related complications. Cen-
tral access lines are a leading cause of iatrogenic infection [57,58] and
are associated with increased ICU stay and mortality [59]. Central
lines also carry an important risk of thrombosis [60] which can lead
to catheter malfunction and requires limited duration anticoagulation,
regardless of whether the catheter is removed. This commitment to
anticoagulation predisposes patients to anticoagulation-related bleed-
ing complications and costs. As a result of these common complica-
tions, providers, and patients should weigh the risks and benefits of
central venous access before pursuing or continuing a line. The first
step in this conscious effort to reduce iatrogenic complications is to
improve the provider’s awareness of the indwelling catheter. A recent
study showed that 21% of physicians were unaware that their patient
had a central venous catheter limiting their ability to make informed
decisions about catheter retention [55]. Repeated daily reassessment
of the need for an indwelling catheter is vital to prevent patient harm
and reduce health care costs.
The eighth CW item of high relevance and importance to the care
of patients with blood diseases is another recommendation from
ASCO. ASCO recommends against the use of white cell stimulating
factors (WCSFs) for the primary prevention of neutropenia in
patients receiving nondose-dense chemotherapy with less than a 20%
risk of neutropenia. Many patients with indolent lymphoma fit in
this low risk category. In some patient populations WCSFs are associ-
ated with a decreased risk of hospitalization and possibly with a
decreased risk of infection. However, improvements in survival have
not been demonstrated in any populations [60]. WCSFs are expensive
and even in patients with a greater than 20% risk of neutropenia,
such as patients with diffuse large B cell lymphoma, the use of
WCSFs has an unfavorable cost-effectiveness profile [61]. As well,
this therapy can cause moderate to severe bone pain. Finally, some
patients have to bear the cost of WCSFs themselves, contributing to
the financial burden of their cancer therapy. Thus, hematologists are
advised to consider the relative risks, benefits, and cost of WCSFs
before prescribing them.
The ninth item on our list of high priority CW items is a recom-
mendation from the American College of Preventive Medicine which
advises clinicians to not use expensive medications when an equally
effective and lower-cost medication is available. This recommendation
is especially important to hematologists given the rapid pace of
change in our field and the introduction of many life-saving, but high
cost medications. Targeted oral chemotherapy drugs and new oral
anticoagulants are examples where multiple treatment options exists,
some of which are associated with very high costs. Health care
expenses are the leading cause of bankruptcy in the United States and
patients with cancer appear to be especially at risk [62,63]. The finan-
cial burden of care can lead to nonadherence with treatments [64],
depleted savings, and even to patients cutting back on other necessi-
ties such as food and clothing [65]. Evidence suggests that patients
welcome provider input on ways to decrease their health care costs
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[66], and offering lower cost, equally effective medicines to our
patients is one way that providers can help.
From a societal perspective, drug expenses are an important factor
in the rising cost of cancer care [67]. A recent survey revealed strong
support from key stakeholders in oncology care on the importance of
Medicare developing cost-control measures to limit reimbursement
for drugs where less expensive but equally effective alternatives are
available [68]. Recommending lower cost options that are equally effi-
cacious has three potential benefits: first it can directly contribute to
decreasing a patient’s financial burden, second it can decrease payer
costs freeing up resources for other needs, and third it may indirectly
influence competing products to lower their prices.
The final recommendation highlighted by the ASH CW Task Force
is a suggestion from the American Association for the Study of Liver
Diseases (AASLD). The AASLD recommends that physicians not rou-
tinely transfuse fresh frozen plasma and/or platelets prior to abdomi-
nal paracentesis or endoscopic variceal band ligation. This
recommendation is relevant to hematologists as hematologists may be
called upon to provide advice regarding the need for transfusion in
the above settings. As well, hematologists are often consulted when
hospitals develop policies around periprocedural transfusion.
Our current knowledge of end-stage liver disease indicates that
bleeding in this patient population is a function of not only deranged
hemostasis but perhaps more importantly of hemodynamic alterations
due to portal hypertension, endothelial dysfunction, bacterial infec-
tions, and renal failure. Patients with cirrhosis frequently experience
thrombocytopenia due to portal hypertension, splenomegaly, and
decreased thrombopoietin production; however, in this setting throm-
bocytopenia is usually mild and most patients can undergo low risk
invasive procedures without platelet transfusion [69]. In fact, a plate-
let count of 60 3 109/L in cirrhotic patients is usually sufficient to
preserve thrombin generation comparable to a healthy subject [70].
Similarly, patients with liver disease often have a prolonged pro-
thrombin time (PT) and an increased international normalized ratio
(INR); however, PT/INR is a poor measure of bleeding risk in this
setting. In liver disease, primary hemostasis, coagulation, and fibrino-
lysis are disrupted in a manner which impacts both endogenous pro-
and anticoagulants [71], routine hemostasis tests fail to predict bleed-
ing tendency in liver disease. Contrary to popular belief, patients with
chronic liver disease are not naturally “autoanticoagulated”. Patients
with cirrhosis are generally not protected from and may even be at
increased risk for thrombosis, particularly in the splanchnic vessel
bed. Furthermore, the ability of plasma or platelet transfusions to pre-
vent or stop bleeding in patients with cirrhosis is unproven. Thus, the
use of blood products to “correct” a perceived bleeding propensity
may expose patients to a risk of adverse events with little expectation
of benefit.
In addition, unnecessary transfusion is expensive and may contrib-
ute to blood product shortages. Platelet concentrates in particular
have a relatively short shelf-life and the blood system is especially
vulnerable to platelet shortages. Clinicians are advised to use past and
current bleeding events to assess bleeding risk and to avoid the rou-
tine use of blood products prior to low risk procedures in patients
with liver disease.
The ASH CW task force developed a method to identify CW rec-
ommendations from other societies that are both relevant and impor-
tant to the practice of hematology and used this method to develop a
top ten list of non-ASH Choosing Wisely recommendations. The rec-
ommendations highlighted through this process come from a broad
range of parent societies, underlining the collaborative and cross-
cutting nature of medical practice. It is likely that other branches of
medicine may similarly find relevance and utility in CW recommen-
dations from outside their own field. The method we have developed
could be easily adapted to identify recommendations relevant and
important to other medical fields and thereby further extend the les-
sons and impact of the ABIM Choosing Wisely campaign.
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